Effects of prenatal opioid exposure on infant brain development
UAB Outcomes of Babies with Opioid Exposure (OBOE study)
The OBOE study is looking at how being exposed to opioids before birth affects babies' brain development, and it follows both babies who were exposed and those who weren't for the first two years to learn more about their growth and the environments they grow up in.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10999598 on NIH RePORTER |
What this research studies
The OBOE study investigates how prenatal exposure to opioids affects brain development in infants. It follows infants with and without such exposure from birth to two years of age, collecting detailed data on brain structure through advanced neuroimaging techniques and assessing the home environment and maternal mental health. This research aims to understand the long-term neurodevelopmental outcomes of these infants, providing valuable insights into their growth and development.
Who could benefit from this research
Good fit: Ideal candidates for this research are infants who were exposed to opioids during pregnancy as well as those who were not exposed.
Not a fit: Patients who are older than two years or those who were not exposed to opioids during pregnancy may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and interventions for infants affected by prenatal opioid exposure.
How similar studies have performed: Other research has shown promising results in understanding the effects of prenatal substance exposure on child development, indicating that this approach is both relevant and necessary.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Ambalavanan, Namasivayam — University of Alabama at Birmingham
- Study coordinator: Ambalavanan, Namasivayam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.